Published in J Clin Oncol on June 21, 2010
European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int (2012) 4.88
Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. JAMA Intern Med (2014) 2.20
Oral bisphosphonate use and risk of postmenopausal endometrial cancer. J Clin Oncol (2015) 1.97
Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol (2011) 1.84
Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol (2012) 1.57
Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst (2012) 1.39
Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates. Nat Rev Clin Oncol (2013) 1.20
Exposure to oral bisphosphonates and risk of cancer. Int J Cancer (2012) 1.17
Individualizing osteoporosis therapy. Osteoporos Int (2012) 1.15
Real-time intravital imaging establishes tumor-associated macrophages as the extraskeletal target of bisphosphonate action in cancer. Cancer Discov (2014) 1.09
Bisphosphonate use after estrogen receptor-positive breast cancer and risk of contralateral breast cancer. J Natl Cancer Inst (2011) 1.08
A prospective study of bisphosphonate use and risk of colorectal cancer. J Clin Oncol (2012) 1.00
Bisphosphonate treatment and risk of esophageal cancer: a meta-analysis of observational studies. Osteoporos Int (2012) 0.92
Association between refill compliance to oral bisphosphonate treatment, incident fractures, and health care costs--an analysis using national health databases. Osteoporos Int (2013) 0.92
A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study. PLoS One (2012) 0.91
Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay. BMC Cancer (2012) 0.89
Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging (2010) 0.88
Exposure to bisphosphonates and risk of cancer: a protocol for nested case-control studies using the QResearch primary care database. BMJ Open (2012) 0.87
Exposure to bisphosphonates and risk of common non-gastrointestinal cancers: series of nested case-control studies using two primary-care databases. Br J Cancer (2013) 0.86
Can oral bisphosphonates really reduce the risk of breast cancer in healthy women? J Clin Oncol (2010) 0.85
Bisphosphonates in the adjuvant setting of breast cancer therapy--effect on survival: a systematic review and meta-analysis. PLoS One (2013) 0.84
Oral bisphosphonate use and colorectal cancer incidence in the Women's Health Initiative. J Bone Miner Res (2013) 0.84
Retracted Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opin Pharmacother (2011) 0.83
Bisphosphonates and pathologic complete response to taxane- and anthracycline-based neoadjuvant chemotherapy in patients with breast cancer. Cancer (2011) 0.82
Prevention of bone metastases and management of bone health in early breast cancer. Breast Cancer Res (2010) 0.81
Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there? J Bone Oncol (2012) 0.81
Effect of adjuvant bisphosphonates on disease-free survival in early breast cancer: Retrospective analysis results in an unselected single-center cohort. J Bone Oncol (2013) 0.78
Tissue phosphoproteomics with PolyMAC identifies potential therapeutic targets in a transgenic mouse model of HER2 positive breast cancer. Electrophoresis (2014) 0.78
Pathophysiology of Bone Remodelling and Current Therapeutic Approaches. Geburtshilfe Frauenheilkd (2012) 0.77
Medical prevention of breast cancer. Breast Care (Basel) (2014) 0.77
The carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studies. PLoS One (2015) 0.77
Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status. Int J Cancer (2015) 0.77
Does estrogen play a role in response to adjuvant bone-targeted therapies? J Bone Oncol (2013) 0.76
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction. Cancers (Basel) (2012) 0.76
Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci (2016) 0.75
AGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011. Breast Care (Basel) (2011) 0.75
Dosing of zoledronic acid with its anti-tumor effects in breast cancer. J Bone Oncol (2015) 0.75
Long-term oral bisphosphonate use in relation to fracture risk in postmenopausal women with breast cancer: findings from the Women's Health Initiative. Menopause (2016) 0.75
Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol (2017) 0.75
From bone to breast and back - the bone cytokine RANKL and breast cancer. Breast Cancer Res (2011) 0.75
Bone-targeted therapy in metastatic breast cancer - all well-established knowledge? Breast Care (Basel) (2014) 0.75
Improving management of patients with advanced cancer. Patient Prefer Adherence (2010) 0.75
Decreased risk of breast cancer associated with oral bisphosphonate therapy. Breast Cancer (Dove Med Press) (2012) 0.75
Better contralateral breast cancer risk estimation and alternative options to contralateral prophylactic mastectomy. Int J Womens Health (2015) 0.75
Cancer: Bisphosphonate use and breast cancer. Nat Rev Endocrinol (2010) 0.75
A virtual approach to evaluate therapies for management of multiple myeloma induced bone disease. Int J Numer Method Biomed Eng (2015) 0.75
[Evidence of the action of bisphosphonates in the prevention of breast cancer]. Rev Assoc Med Bras (2011) 0.75
Prevention and treatment of bone fragility in cancer patient. Clin Cases Miner Bone Metab (2015) 0.75
oral bisphosphonate use may protect women from breast cancer. Nat Rev Clin Oncol (2010) 0.75
Long-Term Oral Bisphosphonate Therapy and Fractures in Older Women: The Women's Health Initiative. J Am Geriatr Soc (2017) 0.75
Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. PLoS One (2017) 0.75
Bone Metastases: An Overview. Oncol Rev (2017) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst (1989) 19.87
Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet (1999) 7.72
Implementation of the Women's Health Initiative study design. Ann Epidemiol (2003) 7.30
Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med (1998) 6.09
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol (2002) 3.01
Factors associated with 5-year risk of hip fracture in postmenopausal women. JAMA (2007) 2.81
Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst (2010) 2.80
Pharmacologic treatment of low bone density or osteoporosis to prevent fractures: a clinical practice guideline from the American College of Physicians. Ann Intern Med (2008) 2.69
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol (1998) 2.60
National Institutes of Health State-of-the-Science Conference statement: Diagnosis and Management of Ductal Carcinoma In Situ September 22-24, 2009. J Natl Cancer Inst (2010) 2.59
Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA (1996) 2.53
Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients. Acta Oncol (2004) 2.48
Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients. Clin Cancer Res (2007) 2.18
Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer (2000) 2.12
Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol (2006) 1.96
Prescribing of hormone therapy for menopause, tibolone, and bisphosphonates in women in the UK between 1991 and 2005. Eur J Clin Pharmacol (2007) 1.88
Hip bone density predicts breast cancer risk independently of Gail score: results from the Women's Health Initiative. Cancer (2008) 1.84
Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist (2008) 1.77
Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Ann Oncol (2008) 1.59
Effect of the Women's Health Initiative on osteoporosis therapy and expenditure in Medicaid. J Bone Miner Res (2006) 1.43
Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more. Expert Opin Biol Ther (2008) 1.12
Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporos Int (2008) 1.06
Bisphosphonates antagonise bone growth factors' effects on human breast cancer cells survival. Br J Cancer (2003) 1.05
Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncol (2008) 0.99
Prevention of ER-negative breast cancer. Recent Results Cancer Res (2009) 0.93
Alendronate suppresses tumor angiogenesis by inhibiting Rho activation of endothelial cells. Biochem Biophys Res Commun (2007) 0.90
Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer. J Clin Oncol (2009) 0.88
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med (2007) 18.27
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med (2013) 15.58
Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care (2007) 14.35
Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA (2006) 12.47
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Selective killing of oncogenically transformed cells through a ROS-mediated mechanism by beta-phenylethyl isothiocyanate. Cancer Cell (2006) 10.10
Maternal and perinatal outcomes associated with a trial of labor after prior cesarean delivery. N Engl J Med (2004) 9.62
Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet (2010) 8.89
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
Association of urinary bisphenol A concentration with medical disorders and laboratory abnormalities in adults. JAMA (2008) 8.44
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Understanding cancer treatment and outcomes: the Cancer Care Outcomes Research and Surveillance Consortium. J Clin Oncol (2004) 7.02
The case for early detection. Nat Rev Cancer (2003) 6.96
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (2008) 6.87
A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med (2012) 6.85
Effects of Testosterone Treatment in Older Men. N Engl J Med (2016) 6.66
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
Bone-density testing interval and transition to osteoporosis in older women. N Engl J Med (2012) 5.81
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75
Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity. Am J Obstet Gynecol (2002) 5.73
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol (2009) 5.59
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care (2011) 5.50
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Effects of estrogen with and without progestin on urinary incontinence. JAMA (2005) 5.41
Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (2003) 5.38
Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med (2008) 5.34
Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol (2008) 5.28
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Comparison of 2 frailty indexes for prediction of falls, disability, fractures, and death in older women. Arch Intern Med (2008) 5.14
High-trauma fractures and low bone mineral density in older women and men. JAMA (2007) 5.00
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Effects of aerobic exercise on mild cognitive impairment: a controlled trial. Arch Neurol (2010) 4.78
American Cancer Society Guidelines on Nutrition and Physical Activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin (2006) 4.69
BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res (2003) 4.64
Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care (2006) 4.62
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Weight loss in breast cancer patient management. J Clin Oncol (2002) 4.51
The Aging, Demographics, and Memory Study: study design and methods. Neuroepidemiology (2005) 4.44
Dynamic visualization of thrombopoiesis within bone marrow. Science (2007) 4.35
Leukocyte count as a predictor of cardiovascular events and mortality in postmenopausal women: the Women's Health Initiative Observational Study. Arch Intern Med (2005) 4.24
Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial. Am J Obstet Gynecol (2002) 4.18
The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res (2012) 4.15
Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst (2004) 4.09
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition. Proc Natl Acad Sci U S A (2009) 4.02
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst (2012) 3.87
Socioeconomic position and health among persons with diabetes mellitus: a conceptual framework and review of the literature. Epidemiol Rev (2004) 3.74
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin (2006) 3.67
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol (2009) 3.58
Diet-quality scores and plasma concentrations of markers of inflammation and endothelial dysfunction. Am J Clin Nutr (2005) 3.55